Source-grounded facts extracted from IDEXX LABORATORIES INC /DE's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
IDEXX LABORATORIES INC /DE shareholders rejected Shareholder proposal to give shareholders the ability to call for a special shareholder meeting at the 2026-05-12 meeting.
“Proposal Six: Shareholder Proposal to Give Shareholders the Ability to Call for a Special Shareholder Meeting. For 28,179,566 Against 40,019,951 Abstain 227,294 Broker Non-Votes 4,524,699”
IDEXX LABORATORIES INC /DE shareholders approved Amendment to Certificate of Incorporation to provide shareholders owning 25% of shares continuously for at least one year the right to have the Corporation call a special meeting at the 2026-05-12 meeting.
“Proposal Five: Amendment to Certificate of Incorporation to Provide Shareholders Owning 25% of the Shares of our Capital Stock the Right to Have IDEXX Call a Special Meeting. For 63,934,239 Against 690,137 Abstain 3,802,435 Broker Non-Votes 4,524,699”
IDEXX LABORATORIES INC /DE shareholders approved Amendment to Certificate of Incorporation to declassify the Board at the 2026-05-12 meeting.
“Proposal Four: Amendment to Certificate of Incorporation to Declassify the Board. For 68,306,553 Against 61,880 Abstain 58,378 Broker Non-Votes 4,524,699”
IDEXX LABORATORIES INC /DE shareholders approved Advisory vote to approve executive compensation at the 2026-05-12 meeting.
“Proposal Three: Advisory Vote to Approve Executive Compensation. For 64,399,156 Against 3,954,026 Abstain 73,629 Broker Non-Votes 4,524,699”
IDEXX LABORATORIES INC /DE shareholders approved Ratification of the appointment of PricewaterhouseCoopers LLP as independent registered accounting firm at the 2026-05-12 meeting.
“Proposal Two: Ratification of Appointment of Independent Registered Public Accounting Firm. For 67,630,771 Against 5,285,163 Abstain 35,576 Broker Non-Votes N/A”
IDEXX LABORATORIES INC /DE shareholders approved Election of Daniel M. Junius, Lawrence D. Kingsley and Sophie V. Vandebroek, PhD as Class II directors at the 2026-05-12 meeting.
“Proposal One: Election of Directors. Daniel M. Junius 64,788,207 3,589,314 49,290 4,524,699 Lawrence D. Kingsley 62,912,441 5,466,952 47,418 4,524,699 Sophie V. Vandebroek, PhD 60,951,897 7,383,566 91,348 4,524,699”
IDEXX LABORATORIES INC /DE: Amended and restated By-Laws effective upon filing of Certificate of Amendment to incorporate declassification of the Board, procedures for special meetings, and other technical changes (effective 2026-05-13).
“On May 13, 2026, pursuant to the Board’s prior approval of certain amendments to our By-Laws, the effectiveness of which were conditioned upon and subject to the filing of a Certificate of Amendment reflecting the Approved Amendments with the Secretary of State of the State of Delaware, the Corporation’s By-Laws were amended and restated effective upon the filing of the aforementioned Certificate of Amendment (the “Amended and Restated By-Laws”).”
IDEXX LABORATORIES INC /DE: Approved amendments to Certificate of Incorporation to declassify the Board over three years and provide for annual election of all directors starting at 2029 annual meeting, and to allow shareholders owning at least 25% of capital stock continuously for one year to call a special meeting (effective 2026-05-13).
“A Certificate of Amendment reflecting the Approved Amendments was filed with the Secretary of State of the State of Delaware and became effective on May 13, 2026.”
IDEXX LABORATORIES INC /DE reported the quarter ended March 31, 2026 results: revenue $1,141 million, EPS $3.47. Guidance raised.
“Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced first quarter results. First Quarter Results The Company reports revenues of $1,141 million for the first quarter of 2026, an increase of 14% as reported and 11% organic, driven by Companion Animal Group ("CAG") growth of 15% as reported and 12% organic. First quarter”
Dr. Asha Collins resigned as Director at IDEXX LABORATORIES INC /DE.
“On February 13, 2025, Dr. Asha Collins resigned from the Board of Directors (the “Board”) of IDEXX Laboratories, Inc. (the “Company”), effective immediately.”
Andrew Emerson was appointed as Executive Vice President, Chief Financial Officer and Treasurer at IDEXX LABORATORIES INC /DE.
“the Board appointed Andrew Emerson, currently Senior Vice President, Corporate and Companion Animal Group (“CAG”) Finance of the Company, as Executive Vice President, Chief Financial Officer and Treasurer of the Company, effective March 1, 2025.”
Brian P. McKeon departed as Executive Vice President, Chief Financial Officer and Treasurer at IDEXX LABORATORIES INC /DE.
“Brian P. McKeon, Executive Vice President, Chief Financial Officer and Treasurer of IDEXX Laboratories, Inc. (the “Company” or “IDEXX”) notified the Company that he will retire from IDEXX effective June 1, 2025.”
Jonathan W. Ayers resigned as Member of the Board of Directors at IDEXX LABORATORIES INC /DE.
“On November 8, 2024, Jonathan W. Ayers, a member of the Board of Directors (the “Board”) of IDEXX Laboratories, Inc. (the “Company”), resigned from the Board and its finance committee, effective November 8, 2024.”
IDEXX LABORATORIES INC /DE shareholders approved Shareholder Proposal Regarding Simple Majority Vote at the 2024-05-06 meeting.
“Proposal Four: Shareholder Proposal Regarding Simple Majority Vote. For 61,364,120 Against 6,382,985 Abstain 673,000 Broker Non-Votes 5,462,716”
IDEXX LABORATORIES INC /DE shareholders approved Advisory Vote to Approve Executive Compensation at the 2024-05-06 meeting.
“Proposal Three: Advisory Vote to Approve Executive Compensation. For 64,265,443 Against 4,412,055 Abstain 458,539 Broker Non-Votes 5,462,716”
IDEXX LABORATORIES INC /DE shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2024-05-06 meeting.
“Proposal Two: Ratification of Appointment of Independent Registered Public Accounting Firm. For 70,547,786 Against 3,857,651 Abstain 193,316 Broker Non-Votes N/A”
IDEXX LABORATORIES INC /DE shareholders approved Election of Irene Chang Britt, Bruce L. Claflin, Asha S. Collins, PhD and Sam Samad, each as a Class I director at the 2024-05-06 meeting.
“Proposal One: Election of Directors. Nominees For Against Abstain Broker Non-Votes Irene Chang Britt 68,830,275 114,870 190,892 5,462,716 Bruce L. Claflin 64,539,198 4,403,367 193,562 5,462,716 Asha S. Collins, PhD 67,054,357 1,892,248 189,432 5,462,716 Sam Samad 65,193,479 3,748,617 193,941 5,462,716”
IDEXX LABORATORIES INC /DE reported the quarter ended March 31, 2024 results: revenue $964 million, EPS $2.81. Guidance reaffirmed.
“Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced first quarter results. First Quarter Results The Company reports revenues of $964 million for the first quarter of 2024, an increase of 7% as reported and organic, driven by Companion Animal Group ("CAG") growth of 7% as reported and organic, and Water revenue growth”
IDEXX LABORATORIES INC /DE updated its the quarter and year ended December 31, 2023 guidance (initiated).
“IDEXX Laboratories, Inc. (the “Company”) announced its financial results for the quarter and year ended December 31, 2023.”
James F. Polewaczyk departed as Executive Vice President and Chief Commercial Officer at IDEXX LABORATORIES INC /DE.
“On December 5, 2023, James F. Polewaczyk, Executive Vice President and Chief Commercial Officer of IDEXX Laboratories, Inc. (the “Company”), notified the Company of his intent to retire after more than 17 years of dedicated leadership and service, effective April 1, 2024.”
IDEXX LABORATORIES INC /DE reported second quarter of 2023 results: revenue $944 million, EPS $2.67. Guidance raised.
“The Company reports revenues of $944 million for the second quarter of 2023”
Irene Chang Britt was elected as Class I Director at IDEXX LABORATORIES INC /DE.
“On July 11, 2023 the board of directors (the “Board”) of IDEXX Laboratories, Inc. (the “Company”) elected Irene Chang Britt as an independent Class I Director”
IDEXX LABORATORIES INC /DE shareholders approved Advisory vote on frequency of approval of executive compensation at the 2023-05-17 meeting.
“Proposal Four: Advisory Vote on Frequency of Approval of Executive Compensation. One Year 64,021,474 Two Years 39,624 Three Years 4,892,200 Abstain 141,983 Broker Non-Votes 5,389,472”
IDEXX LABORATORIES INC /DE shareholders approved Advisory vote to approve executive compensation at the 2023-05-17 meeting.
“Proposal Three: Advisory Vote to Approve Executive Compensation. For 65,447,348 Against 3,468,812 Abstain 179,121 Broker Non-Votes 5,389,472”
IDEXX LABORATORIES INC /DE shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm at the 2023-05-17 meeting.
“Proposal Two: Ratification of Appointment of Independent Registered Public Accounting Firm. For 69,344,656 Against 5,020,277 Abstain 119,820 Broker Non-Votes N/A”
IDEXX LABORATORIES INC /DE shareholders approved Election of Class II directors at the 2023-05-17 meeting.
“Proposal One: Election of Directors. Nominees For Against Abstain Broker Non-Votes Daniel M. Junius 67,487,826 1,473,426 134,029 5,389,472 Lawrence D. Kingsley 65,340,069 3,621,033 134,179 5,389,472 Sophie V. Vandebroek, PhD 61,997,790 6,964,093 133,398 5,389,472”
IDEXX LABORATORIES INC /DE reported full year 2023 results: revenue $3,615 million - $3,700 million, EPS $9.33 - $9.75. Guidance raised.
“Increases 2023 revenue guidance to $3,615 million - $3,700 million, reflecting 7.5% - 10% growth as reported and organically Updates 2023 EPS outlook to $9.33 - $9.75, a year-over-year increase of 16% - 22% as reported and 20% - 26% on a comparable basis, including ~12% combined growth benefit from a customer contract resolution payment in Q1 2023 and lapping of discrete 2022 R&D investments”
IDEXX LABORATORIES INC /DE reported quarter ended March 31, 2023 results: revenue $900 million, EPS $2.55.
“First Quarter Results The Company reports revenues of $900 million for the first quarter of 2023, an increase of 8% reported and 10% organic, driven by Companion Animal Group ("CAG") Diagnostics recurring revenue growth of 9% reported and 12% organic. First quarter results were supported by continued solid demand for veterinary services and benefits from strong IDEXX execution, reflected in 14% reported and organic growth in U.S. CAG Diagnostics recurring revenues and double-digit organic gains across IDEXX's major testing modalities. IDEXX innovation and commercial engagement drove record first quarter global premium instrument placements, supporting 11% annual growth in IDEXX's global premium instrument installed base. Veterinary software, services and diagnostic imaging systems revenue grew 13% as reported and 14% organically, reflecting high growth in recurring revenues and continued strong quarterly placements of cloud-based software solutions. Overall first quarter revenue gains”
IDEXX LABORATORIES INC /DE updated its the quarter and year ended December 31, 2022 guidance (initiated).
“IDEXX Laboratories, Inc. (the “Company”) announced its financial results for the quarter and year ended December 31, 2022.”
IDEXX LABORATORIES INC /DE reported the quarter ended September 30, 2022 results: revenue $842 million, EPS $2.15. Guidance reaffirmed.
“The Company reports revenues of $842 million for the third quarter of 2022, a 4% increase as reported and 8% organically, driven by Companion Animal Group ("CAG") Diagnostics recurring revenue growth of 5% reported and 9% organic, building on strong prior year performance.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.